Abstract
Background Enlarged vestibular aqueduct (EVA) is a common inner ear malformation that can cause sensorineural hearing loss. It is frequently associated with mutations in the SLC26A4 gene. This study aimed to investigate the genetic basis of hearing loss in Mongolian patients with EVA.
Methods Whole exome sequencing was performed in 19 Mongolian patients from 15 unrelated families diagnosed with EVA with/without cochlear incomplete partition type II. All patients underwent high-resolution computed tomography of the temporal bone to confirm the diagnosis.
Results Biallelic SLC26A4 pathogenic variants were identified in all 15 families (100%). The most frequent variant was c.919-2A>G (40%), followed by c.2027T>A (23.3%) and c.1318A>T (16.7%). Population-specific variants in East Asians (c.919-2A>G), North Asians (c.2027T>A), and Southwest Asians (c.716T>A) were all present in Mongolian patients, demonstrating a panethnic mutation spectrum. Digenic inheritance was not observed. There was no clear genotype-phenotype correlation between specific SLC26A4 genotypes and hearing levels or inner ear malformations.
Conclusions This study provides a comprehensive overview of the genetic landscape of EVA in the Mongolian population. The identification of biallelic SLC26A4 pathogenic variants in all families highlights the importance of this gene in the pathogenesis of EVA. The unique mutation spectrum observed in this study may reflect the genetic diversity resulting from historical migrations of Mongolians.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by research grants from the National Science and Technology Council of the Executive Yuan of Taiwan (NSTC 110-2923-B-002-001-MY3, Chen-Chi Wu), the Hsinchu Science Park Bureau (B113007, Chen-Chi Wu), the National Health Research Institutes (NHRI-EX113-11311PI, Chen-Chi Wu), and the Mongolian Foundation for Sciences and Technology (TWN2020/002, Jargalkhuu Erdenechuluun).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the National Taiwan University Hospital Research Ethics Committee (202007065RINB) and EMJJ Otolaryngology Hospital of Mongolia (Medical Ethics Committee of the Ministry of Health, Mongolia (No: 23/065)).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos